2011年8月
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis
MODERN RHEUMATOLOGY
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 21
- 号
- 4
- 開始ページ
- 436
- 終了ページ
- 439
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1007/s10165-011-0416-9
- 出版者・発行元
- SPRINGER
Ankylosing spondylitis (AS) is a chronic inflammatory osteoarticular disease. Although the etiology remains unknown, proinflammatory cytokines, such as tumor necrosis factor alpha and interleukin-6, have been implicated in the development of AS. Here, we report that a patient with AS, whose disease had been refractory to conventional treatment regimens and who needed to receive continuous corticosteroid, responded well to tocilizumab. While further clinical evaluation is required, tocilizumab may be an optional treatment for AS.
- リンク情報
-
- DOI
- https://doi.org/10.1007/s10165-011-0416-9
- CiNii Articles
- http://ci.nii.ac.jp/naid/10029513134
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/21308388
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000293709300018&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1007/s10165-011-0416-9
- ISSN : 1439-7595
- CiNii Articles ID : 10029513134
- PubMed ID : 21308388
- Web of Science ID : WOS:000293709300018